Berotralstat reduces HAE attacks regardless of baseline attack rates, prior treatment
09 Mar 2021
byAudrey Abella
Subgroup analyses of the phase III APeX-2 trial presented at AAAAI 2021 showed that use of the oral plasma kallikrein inhibitor berotralstat led to consistent reductions in attack frequency in patients with hereditary angioedema (HAE), irrespective of baseline attack rates and prior prophylaxis.
Berotralstat reduces HAE attacks regardless of baseline attack rates, prior treatment
09 Mar 2021
